CROSSJECT Company Crossject Deutsche Boerse AG
Equities
74C
FR0011716265
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.826 EUR | +2.70% |
|
+16.16% | -59.78% |
| 10/07 | Markets Powered by Alternating Current |  |
| 10/07 | Crossject Gets EUR7 Million Public Funding for New Epinephrine Product | MT |
Business Summary
Number of employees: 105
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Needle-free Injection System
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -84.80% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
France
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -84.80% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 08/01/08 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 01/16/01 |
| General Counsel | - | 01/13/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 07/23/07 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
Yannick Plétan
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 37,086,652 | 27,118,311 ( 73.12 %) | 135,869 ( 0.3664 %) | 73.12 % |
| Stock B | 0 | 1,655,925 | 0 | 0 |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
CROSSJECT 0.26% | 107,541 | 0.26% | 187,408 $ |
Company contact information
Sector
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.978
EUR
Average target price
4.3
EUR
Spread / Average Target
+117.39%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.50% | 261M |
- Stock Market
- Equities
- ALCJ Stock
- 74C Stock
- Company Crossject
